The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of PI3K-pathway–activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.
Debora Fumagalli
No relevant relationships to disclose
Vinu Jose
No relevant relationships to disclose
Roberto Salgado
No relevant relationships to disclose
Stefan Michiels
No relevant relationships to disclose
Timothy R. Wilson
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche
Carol O'Brien
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Ling Huw
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Ghizlane Rouas
No relevant relationships to disclose
Carmen Criscitiello
No relevant relationships to disclose
Lina Pugliano
No relevant relationships to disclose
Martine J. Piccart-Gebhart
No relevant relationships to disclose
Mark R. Lackner
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Sherene Loi
No relevant relationships to disclose
Christos Sotiriou
No relevant relationships to disclose